The merger consideration tells the story: Neuphoria Therapeutics (Nasdaq: NEUP) stockholders receive 14.5 per cent of the combined entity in an all-share deal announced July 23, 2026, in exchange for contributing a Nasdaq listing and at least $10 million in cash to Scancell Holdings. The offsetting argument is that Scancell arrives with a 77 per cent Progression Free Survival figure at 22 months in advanced melanoma and up to $89 million in new financing to push that number through a registrational Phase 3 trial.
Deal mechanics and what NEUP holders actually get
Scancell will acquire Neuphoria in a transaction approved unanimously by both boards, with completion targeted for late Q4 2026. The Merger consideration is 20,414,065 ADSs (representing 204,140,654 Consideration Shares), priced at $0.1205 per ADS or Ordinary Share, representing approximately 13.7 per cent of Scancell's enlarged issued Ordinary Share capital at completion. The combined company will seek a Nasdaq listing under the ticker "SCLT" while retaining Scancell's existing AIM listing under the symbol SCLP.
Neuphoria stockholders also receive Contingent Value Rights (CVRs) tied to milestones on Neuphoria's partnered assets, certain intellectual property monetisation events, and an Australian R&D tax credit for the year ended June 30, 2026. Neuphoria Chairman Alan Fisher said the transaction offers stockholders the opportunity to participate in Scancell's oncology pipeline while preserving potential upside from Neuphoria's assets through those CVRs.
The financing stack
The $89 million headline breaks into four tranches. A committed $39.1 million Private Placement covers 324,190,865 new Ordinary Shares and Non-Voting Ordinary Shares. A UK Placing targets approximately $12.0 million and a Retail Offer is capped at $3.0 million. A non-binding term sheet with funds and accounts managed by BlackRock covers up to $25 million in Debt Financing. Neuphoria's existing cash contributes at least $10 million at close. Pro forma net cash is approximately $79.1 million before transaction costs, extending runway into 2029.
The capital has one destination: funding the registrational Phase 3 study for iSCIB1+ through the primary readout, targeted for H2 2028. Scancell's Chief Executive Officer Dr Phil L'Huillier said the financing provides the capital required to execute that study while establishing Scancell's access to US investors.
The counterargument
The counterargument is structural. A 14.5 per cent stake in a pre-Phase-3 asset is a specific risk profile, and CVRs add conditionality rather than certainty. Multiple conditions must clear before any of this materialises: Scancell shareholder approval at an EGM, Neuphoria stockholder approval at a special meeting, SEC review of the Nasdaq listing, and AIM admission for the Consideration Shares. Scancell is using Neuphoria as a listing vehicle, concentrating execution risk inside the US regulatory process.
On balance
On balance, the 77 per cent Progression Free Survival figure is the number carrying the deal. Further SCOPE Phase 2 data, expected within the next 12 months, will extend or complicate it. The line to watch: whether that update, combined with a $79.1 million cash position and a BlackRock debt facility behind it, holds institutional attention through the H2 2028 Phase 3 primary readout.